First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Clinical trial NCT05216432 · RECRUITING

Trial details

NCT number: NCT05216432
Sponsor: Relay Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

PIK3CA Mutation Solid Tumor, Adult HER2-negative Breast Cancer Breast Cancer Metastatic Breast Cancer Advanced Breast Cancer Unresectable Solid Tumor

Start date: 2021-12-08
Primary completion: 2027-04-30
Enrollment: 930

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.